<DOC>
	<DOCNO>NCT01520506</DOCNO>
	<brief_summary>The Covidien OneShot™ ablation system use deliver low-level radio frequency ( RF ) energy wall renal artery denervate human kidney .</brief_summary>
	<brief_title>Rapid Renal Sympathetic Denervation Resistant Hypertension</brief_title>
	<detailed_description>Unique OneShot™ ablation system ability deliver desire helical treatment pattern optimal Renal Denervation ( RDN ) single balloon based-treatment , eliminate user variance inherent currently available point-by-point approach . In addition , technological improvement incorporate . The OneShot™ RF generator touchscreen , user friendly interface ; catheter advancement make safe use guidewire ; two radiopaque marker catheter enable precise device positioning ; irrigate catheter tip reduces risk overheat clot formation RF delivery . By offer reliable single treatment approach , couple enhance ease-of use reduce procedure time , technology potential significantly expand clinical adoption catheter-based renal sympathetic denervation .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<criteria>1 . Systolic blood pressure ≥ 160 mmHg despite treatment regimen 3 antihypertensive medication include diuretic stable 2 week prior screen . 2 . Age 1885 year . 3 . Able provide inform consent comply followup visit . 1 . Diameter leave right renal artery le 4 mm great 7mm . 2 . Length target segment leave right renal artery less 20mm . 3 . Other renal arterial abnormality include severe renal artery stenosis , previous renal stenting angioplasty . 4 . Endstage renal disease require dialysis renal transplant . 5. estimate Glomerular Filtration Rate &lt; 45 mL/min per 1.73 m2 . 6 . Type 1 diabetes mellitus . 7 . Myocardial infarction , unstable angina , cerebrovascular event within 6 month prior screen . 8 . Severe valvular heart disease reduction blood pressure would consider hazardous . 9 . Bleeding disorder refuse blood transfusion . 10 . Pregnancy breast feed . 11 . Peripheral vascular disease preclude catheter insertion . 12 . Any serious medical condition , opinion investigator , may adversely affect safety effectiveness participant study . 13 . Current enrollment another investigational drug device Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
	<keyword>Renal Insufficiency</keyword>
</DOC>